$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Therapeutic efficacy of a systemically delivered oncolytic adenovirus - Biodegradable polymer complex

Biomaterials, v.34 no.19, 2013년, pp.4622 - 4631  

Kim, J. ,  Li, Y. ,  Kim, S.W. ,  Lee, D.S. ,  Yun, C.O.

Abstract AI-Helper 아이콘AI-Helper

Despite great efforts to develop a more effective oncolytic adenovirus (Ad) for eradicating tumors, in vivo application via systemic administration is strictly limited to local injection due to host immune responses by Ad surface proteins and liver accumulation by the inherent nature of the Ad. In t...

주제어

참고문헌 (40)

  1. J Gene Med Volpers 6 Suppl. 1 S164 2004 10.1002/jgm.496 Adenoviral vectors for gene transfer and therapy 

  2. Curr Gene Ther Wu 1 101 2001 10.2174/1566523013349002 Cancer gene therapy by adenovirus-mediated gene transfer 

  3. Science Bischoff 274 373 1996 10.1126/science.274.5286.373 An adenovirus mutant that replicates selectively in p53-deficient human tumor cells 

  4. Cancer Gene Ther Kim 9 725 2002 10.1038/sj.cgt.7700494 Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy 

  5. Hum Gene Ther Kim 18 773 2007 10.1089/hum.2006.167 E1A- and E1B-double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects 

  6. Gene Ther Choi 13 1010 2006 10.1038/sj.gt.3302759 Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect 

  7. Mol Ther Zhang 19 1558 2011 10.1038/mt.2011.29 Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF 

  8. Mol Ther Yoo 15 295 2007 10.1038/sj.mt.6300023 VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth 

  9. PLoS One Lee 7 e36520 2012 10.1371/journal.pone.0036520 A novel sLRP6E1E2 inhibits canonical Wnt signaling, epithelial-to-mesenchymal transition, and induces mitochondria-dependent apoptosis in lung cancer 

  10. Hum Gene Ther Muruve 10 965 1999 10.1089/10430349950018364 Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo 

  11. J Gen Virol Alemany 81 2605 2000 10.1099/0022-1317-81-11-2605 Blood clearance rates of adenovirus type 5 in mice 

  12. Mol Pharmacol Noureddini 2 341 2005 10.1021/mp050045c Genetic targeting strategies for adenovirus 

  13. Mol Ther Kiang 14 588 2006 10.1016/j.ymthe.2006.03.024 Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system 

  14. Hum Gene Ther Molnar-Kimber 9 2121 1998 10.1089/hum.1998.9.14-2121 Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma 

  15. J Immunol Sumida 174 7179 2005 10.4049/jimmunol.174.11.7179 Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein 

  16. Crit Rev Ther Drug Carrier Syst Seymour 9 135 1992 Passive tumor targeting of soluble macromolecules and drug conjugates 

  17. Mol Ther Kreppel 16 16 2008 10.1038/sj.mt.6300321 Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide 

  18. BMB Rep Kang 43 781 2010 10.5483/BMBRep.2010.43.12.781 Current advances in adenovirus nanocomplexes: more specificity and less immunogenicity 

  19. Biomaterials Kim 33 1838 2012 10.1016/j.biomaterials.2011.11.020 Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials 

  20. Adv Drug Deliv Rev Choi 64 720 2012 10.1016/j.addr.2011.12.011 Evolution of oncolytic adenovirus for cancer treatment 

  21. Biomaterials Kim 30 658 2009 10.1016/j.biomaterials.2008.10.009 Arginine-grafted bioreducible poly(disulfide amine) for gene delivery systems 

  22. Biomaterials Kim 31 1865 2010 10.1016/j.biomaterials.2009.11.043 The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy 

  23. Cancer Res Matsumura 46 6387 1986 A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs 

  24. J Control Release Shuvaev 149 236 2011 10.1016/j.jconrel.2010.10.026 Modulation of endothelial targeting by size of antibody-antioxidant enzyme conjugates 

  25. Biochim Biophys Acta Maruyama 1128 44 1992 10.1016/0005-2760(92)90255-T Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol) 

  26. Gene Ther Hatakeyama 14 68 2007 10.1038/sj.gt.3302843 Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid 

  27. Adv Drug Deliv Rev Maruyama 63 161 2011 10.1016/j.addr.2010.09.003 Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects 

  28. Biomaterials He 31 3657 2010 10.1016/j.biomaterials.2010.01.065 Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles 

  29. Adv Drug Deliv Rev Torchilin 63 131 2011 10.1016/j.addr.2010.03.011 Tumor delivery of macromolecular drugs based on the EPR effect 

  30. J Natl Cancer Inst Kim 98 1482 2006 10.1093/jnci/djj397 Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy 

  31. Gene Ther Yoo 15 635 2008 10.1038/gt.2008.3 Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition 

  32. Biomaterials Kim 32 9328 2011 10.1016/j.biomaterials.2011.08.066 Bioreducible polymer-conjugated oncolytic adenovirus for hepatoma-specific therapy via systemic administration 

  33. J Virol Roelvink 72 7909 1998 10.1128/JVI.72.10.7909-7915.1998 The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F 

  34. Int J Cancer Kanerva 110 475 2004 10.1002/ijc.20129 Modified adenoviruses for cancer gene therapy 

  35. Biomaterials Kim 32 5158 2011 10.1016/j.biomaterials.2011.03.084 Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA 

  36. Nat Med Ries 6 1128 2000 10.1038/80466 Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015) 

  37. Sanderson 1983 Polar covalence 

  38. Sanderson 1976 Chemical bonds and bond energy 

  39. Mol Ther Zhang 3 697 2001 10.1006/mthe.2001.0329 Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages 

  40. Hum Gene Ther Liu 14 627 2003 10.1089/104303403321618146 The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors 

LOADING...

관련 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로